Artificial technology
Mar 21, 2019
The Business Cocktail
Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
